Jordan Food and Drug Administration (JFDA) Comprehensive Guideline on Good Review Practices (GRevP)

Published By : Jordan Food and Drug Administration | Consultation Type : Other |

Health

Closed

Published Consultation

3/12/2026
Comment End Date

4/12/2026
Consultation Definition

4/13/2026
Consultation Results

4/30/2026

Subject of consultation
Activities
Full legal text

Objectives

This document establishes a comprehensive framework for the implementation of Good Review Practices (GRevP) at the Jordan Food and Drug Administration (JFDA). The objective is to create systematic, consistent, and high-quality processes for the review of medical product applications. This guideline encompasses both main principles and detailed procedures intended to achieve timely, predictable, consistent, transparent, efficient, and high-quality regulatory reviews, thereby facilitating clear and well-justified decision-making throughout the regulatory review process.

Summary

This guideline is issued under the regulatory mandate of the Jordan Food and Drug Administration (JFDA), in accordance with the applicable national legislation and regulations governing the evaluation, authorization, and post-marketing oversight of medicinal products in Jordan. The implementation of Good Review Practices (GRevP) supports JFDA’s commitment to ensuring that regulatory decisions are scientifically robust, transparent, consistent, and aligned with internationally recognized regulatory standards, including those recommended by the World Health Organization. The JFDA review system operates within a comprehensive regulatory framework that encompasses the full lifecycle of medical products, with Good Review Practices implemented in coordination with other regulatory functions, including marketing authorization (MA), variations and lifecycle management, pharmacovigilance integration and signal management, market surveillance and quality defect investigations, outcomes of GMP and GCP inspections, lot release procedures for biological products, and clinical trial oversight and authorization.